FOXD1 is associated with poor outcome and maintains tumor-promoting enhancer-gene programs in basal-like breast cancer.

Kumegawa, Kohei; Yang, Liying; Miyata, Kenichi; Maruyama, Reo.

Afiliação

Kumegawa K; Cancer Cell Diversity Project, NEXT-Ganken Program, Japanese Foundation for Cancer Research, Tokyo, Japan.
Yang L; Project for Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Miyata K; Project for Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Maruyama R; Cancer Cell Diversity Project, NEXT-Ganken Program, Japanese Foundation for Cancer Research, Tokyo, Japan.

Front Oncol ; 13: 1156111, 2023.

Article em En | MEDLINE | ID: mdl-37234983